LivaNova PLC

LivaNova PLC is a medical technology company that designs, develops, manufactures, markets, and sells products, therapies, and services globally. It operates in two segments: Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment offers heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannulae, and related accessories. The Neuromodulation segment provides the VNS Therapy System, an implantable pulse generator that stimulates the vagus nerve, used for treating drug-resistant epilepsy and difficult-to-treat depression. This segment also includes the aura6000 system for obstructive sleep apnea, which is in development and clinical testing.

LivaNova PLC is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol LIVN. Its shares trade in US dollars (USD). The company is headquartered in London, United Kingdom, but its stock is traded on a US exchange, making it accessible to international investors.

LivaNova PLC operates in the Healthcare sector, specifically within the Medical Devices industry. As a medical technology company, it focuses on developing and commercializing products and therapies for cardiopulmonary and neuromodulation applications. This includes devices used in cardiac surgery and neurological disorders such as epilepsy and depression.

LivaNova PLC is headquartered in London, United Kingdom, and operates globally. The company serves perfusionists, neurologists, neurosurgeons, healthcare professionals, hospitals, medical institutions, and healthcare providers. It sells its medical devices through a combination of direct sales representatives, agents, and independent distributors worldwide.

LivaNova PLC generates revenue through two main business segments. The Cardiopulmonary segment sells products such as heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing, and cannulae, along with related services. The Neuromodulation segment generates revenue from the VNS Therapy System, which includes implantable pulse generators and leads for treating epilepsy and depression, as well as surgical equipment. Additionally, the company is developing the aura6000 system for obstructive sleep apnea, which may contribute future revenue upon approval.